Elisa Cascade, CPO at Advarra explains why addressing the challenges faced by clinical research sites is vital for improving ...

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) shared new and updated results from its RESET clinical development ...

The ongoing evolution of real-world evidence from a novel concept to a cornerstone of modern medical research signifies its ...

GU ASCO annual meeting featured a session on emerging trends in germ cell tumors and a presentation by Dr. Darren Feldman discussing the landscape of new trials and targets in refractory germ cell ...

The first four treatments in a platform trial for amyotrophic lateral sclerosis (ALS) failed to reach key endpoints in phase ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...